Securities Law Firm Files Lawsuit Against Centene Corporation and Executives for Potential Violations of Federal Securities Laws

Strategic Insights -

A lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain senior executives for potential violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al. , No. 25-cv-05659.

The lawsuit stems from Centene's alleged misrepresentation of its financial guidance for fiscal year 2025. The company initially announced stability in earnings power but subsequently increased its guidance due to enrollment "overperformance." However, an independent actuarial report revealed lower than expected enrollment growth and increased morbidity rates in the majority of the market that Centene serves. As a result, the price of Centene stock fell by over 40% after the company abruptly withdrew its previous guidance.

Key Takeaways:

  • The lawsuit was filed on behalf of investors who purchased Centene securities, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
  • Centene allegedly misrepresented its financial guidance for fiscal year 2025, initially stating stability in earnings power but subsequently increasing guidance due to enrollment "overperformance."
  • An independent actuarial report revealed lower than expected enrollment growth and increased morbidity rates in the majority of the market that Centene serves.
  • The price of Centene stock fell by over 40% after the company abruptly withdrew its previous guidance.
  • The lawsuit is pending in the U.S. District Court for the Southern District of New York, with a case number of 25-cv-05659.
  • Shareholders represent a class of investors who purchased Centene securities from December 12, 2024, to July 1, 2025.
  • Lead plaintiff, Lunstrum, seeks to represent the class and investigate Centene's alleged misrepresentations.
  • The firm Bleichmar Fonti & Auld LLP is acting as lead counsel for the plaintiffs.

Statistics:

  • The price of Centene stock fell by $22.87 per share, or 40%, from $56.65 per share to $33.78 per share on July 2, 2025.
  • 22 of the 29 states Centene serves were experiencing lower than expected enrollment growth.
  • Morbidity rates in those states were significantly higher than expected.
  • Over $900 million in value was recovered from Tesla, Inc.'s Board of Directors in a recent notable success by Bleichmar Fonti & Auld LLP.
  • Over $420 million was recovered from Teva Pharmaceutical Ind. Ltd. in a recent notable success by Bleichmar Fonti & Auld LLP.

Sources:

  • GlobeNewswire, "Leading Securities Law Firm Announces Lawsuit Against Centene Corporation and Senior Executives"
  • The Legal 500, "Bleichmar Fonti & Auld LLP"
  • ISS SCAS, "Bleichmar Fonti & Auld LLP"
  • Lawdragon, "Bleichmar Fonti & Auld LLP"
  • Law360, "Bleichmar Fonti & Auld LLP"
  • Thomson Reuters, "Bleichmar Fonti & Auld LLP"
  • Corporate Disclosure, "Centene Corporation Announces Financial Guidance for Fiscal Year 2025" (December 12, 2024)